Prostate News and Research

RSS

RNAi screen identifies Brd4 as a therapeutic target for acute myeloid leukemia

Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.

4 Aug 2011

JAMIA highlights several perspectives, five research articles on translational bioinformatics

With the summer edition of JAMIA--currently online at www.JAMIA.org--AMIA's peer-reviewed journal on informatics in biomedicine and health opens the door to translational science, highlighting several perspectives and five research articles on translational bioinformatics (TBI), and suggesting that future publications in greater volume will help keep JAMIA readers abreast of new developments and applications of translational bioinformatics, just as more hospital and academic health centers are embracing molecular measurements for diagnosis and planning therapies.

4 Aug 2011

W.M. Keck Foundation awards Jefferson scientists with $1M medical research grant

Scientists at Thomas Jefferson University have been awarded a $1 million medical research grant from the W.M. Keck Foundation for an ambitious project looking at the little explored 98 percent of the human genome and what role it may play in the onset and progression of diseases.

4 Aug 2011

New urine test can aid in early detection of prostate cancer

A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.

4 Aug 2011

Urine test for prostate cancer: Study

Lead researcher Dr. Scott Tomlins, a pathology resident at the University of Michigan Health System said, “This is a tool that men and their physician can use to help them decide whether it's appropriate to get a biopsy now or delay that decision.”

4 Aug 2011

British scientists find seven new gene variants linked to prostate cancer

Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.

3 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

New device can produce blood-based diagnostic results in minutes

Samuel K. Sia, assistant professor of biomedical engineering at Columbia Engineering, has developed an innovative strategy for an integrated microfluidic-based diagnostic device-in effect, a lab-on-a-chip-that can perform complex laboratory assays, and do so with such simplicity that these tests can be carried out in the most remote regions of the world.

1 Aug 2011

Kenya Medical Services Minister to establish African Cancer Foundation

When Anyang' Nyong'o, Medical Services Minister of Kenya, returned cancer-free to his native land in March of this year, he made a commitment to the people of Kenya. "My experience is a wake-up call for us in Kenya," he proclaimed.

1 Aug 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris Group today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

New approaches to improve biomarker discovery

An article in the current edition of Chemical & Engineering News, ACS's weekly newsmagazine, describes the trials, tribulations, and triumphs of one of the hottest pursuits in modern biomedical science - the search for "biomarkers" that could greatly improve the diagnosis of disease and efforts to monitor the effectiveness of treatment.

28 Jul 2011

MR-guided focused ultrasound prior to radiation therapy could treat cancer

Hypoxic tumor cells usually resist radiation and chemotherapy, making them a key challenge in treating cancer. Researcher Xin Chen, Ph.D. believes that MR-guided focused ultrasound could reduce this problem, benefiting patients with malignant solid tumors in areas such as the liver, prostate and breast.

27 Jul 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Late-stage prostate tumors are driven by different hormonal pathway

UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously.

26 Jul 2011

GlaxoSmithKline files suit against Watson over generic JALYN

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market dutasteride and tamsulosin hydrochloride capsules.

25 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Scripps Research, Jupiter Medical Center partner for cancer study

In a first for both institutions, Jupiter Medical Center, the area's Number One Preferred Hospital, and The Scripps Research Institute, one of the world's largest private, non-profit biomedical research organizations, are teaming up to conduct research on human cancer tissue.

22 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011